NASDAQ:HRTX Heron Therapeutics - HRTX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.73 -0.18 (-9.42%) (As of 03/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.72▼$1.9450-Day Range$1.91▼$3.2552-Week Range$1.72▼$6.38Volume2.02 million shsAverage Volume1.74 million shsMarket Capitalization$205.68 millionP/E RatioN/ADividend YieldN/APrice Target$8.40 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Heron Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside385.5% Upside$8.40 Price TargetShort InterestBearish19.18% of Shares Sold ShortDividend StrengthN/ASustainability-1.96Upright™ Environmental ScoreNews Sentiment0.07Based on 19 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.03) to ($0.43) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.92 out of 5 starsMedical Sector606th out of 995 stocksPharmaceutical Preparations Industry291st out of 482 stocks 3.5 Analyst's Opinion Consensus RatingHeron Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.40, Heron Therapeutics has a forecasted upside of 385.5% from its current price of $1.73.Amount of Analyst CoverageHeron Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted19.18% of the outstanding shares of Heron Therapeutics have been sold short.Short Interest Ratio / Days to CoverHeron Therapeutics has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.Change versus previous monthShort interest in Heron Therapeutics has recently decreased by 2.02%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldHeron Therapeutics does not currently pay a dividend.Dividend GrowthHeron Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHeron Therapeutics has received a 61.27% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Antiemetics and antinauseants (A04)", "Bupivacaine", and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Heron Therapeutics is -1.96. Previous Next 2.3 News and Social Media Coverage News SentimentHeron Therapeutics has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Heron Therapeutics this week, compared to 1 article on an average week.Search Interest16 people have searched for HRTX on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Heron Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Heron Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.02% of the stock of Heron Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Heron Therapeutics are expected to grow in the coming year, from ($1.03) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Heron Therapeutics is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Heron Therapeutics is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHeron Therapeutics has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Heron Therapeutics (NASDAQ:HRTX) StockHeron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in San Diego, CA.Read More Receive HRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address HRTX Stock News HeadlinesMarch 27, 2023 | finance.yahoo.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2022 Earnings Call TranscriptMarch 27, 2023 | americanbankingnews.comEvercore ISI Cuts Heron Therapeutics (NASDAQ:HRTX) Price Target to $10.00March 27, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. March 25, 2023 | americanbankingnews.comNeedham & Company LLC Lowers Heron Therapeutics (NASDAQ:HRTX) Price Target to $7.00March 25, 2023 | americanbankingnews.comHeron Therapeutics (NASDAQ:HRTX) Releases Quarterly Earnings Results, Beats Expectations By $0.08 EPSMarch 24, 2023 | msn.comHeron Therapeutics Dives on Zynrelef TroublesMarch 24, 2023 | msn.comHeron stock falls ~10% as headwinds for Zynrelef label, device delivery lingerMarch 24, 2023 | marketwatch.comHeron Therapeutics Shares Rise Premarket as 4Q Results Top Views >HRTXMarch 27, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. March 24, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Heron Therapeutics (HRTX), Monopar Therapeutics Inc (MNPR) and Werewolf Therapeutics (HOWL)March 24, 2023 | finance.yahoo.comDow futures tick higher, banking crisis weighsMarch 24, 2023 | finance.yahoo.comQ4 2022 Heron Therapeutics Inc Earnings CallMarch 23, 2023 | finance.yahoo.comHeron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate UpdatesMarch 22, 2023 | benzinga.comHeron Therapeutics's Earnings OutlookMarch 22, 2023 | americanbankingnews.comHeron Therapeutics (HRTX) to Release Earnings on ThursdayMarch 13, 2023 | finance.yahoo.comHeron Therapeutics Announces Centers for Medicare & Medicaid Services (CMS) Granted Pass-through Payment Status for APONVIE™, Effective April 1, 2023March 10, 2023 | finance.yahoo.comHeron Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 23, 2023March 6, 2023 | finance.yahoo.comHeron Therapeutics Announces U.S. Commercial Launch of APONVIE™ for the Management of Postoperative Nausea and Vomiting in AdultsFebruary 27, 2023 | finance.yahoo.comHeron Therapeutics Announces Presentation at 43rd Annual Cowen Healthcare ConferenceFebruary 22, 2023 | msn.comHeron gains on agreement with Rubric Capital and Velan CapitalFebruary 22, 2023 | finance.yahoo.comHeron Therapeutics Enters into Cooperation Agreement with Rubric Capital and Velan CapitalFebruary 18, 2023 | seekingalpha.comHRTX Heron Therapeutics, Inc.February 7, 2023 | msn.comHeron Therapeutics Flies Upward on New InvestorsJanuary 30, 2023 | finance.yahoo.comThe past three years for Heron Therapeutics (NASDAQ:HRTX) investors has not been profitableJanuary 24, 2023 | reuters.comHRTX.A - | Stock Price & Latest News | ReutersJanuary 23, 2023 | nasdaq.comJpmorgan Chase & Co Updates Holdings in Heron Therapeutics Inc (HRTX)January 9, 2023 | finance.yahoo.comHeron Therapeutics Highlights Progress in Acute Care and Oncology Care FranchisesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive HRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address HRTX Company Calendar Last Earnings3/23/2023Today3/27/2023Next Earnings (Estimated)5/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HRTX CUSIPN/A CIK818033 Webwww.herontx.com Phone(858) 251-4400Fax650-365-6490Employees302Year Founded1983Price Target and Rating Average Stock Price Forecast$8.40 High Stock Price Forecast$12.00 Low Stock Price Forecast$5.50 Forecasted Upside/Downside+403.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-220,680,000.00 Net Margins-169.05% Pretax Margin-220.55% Return on Equity-2,213.33% Return on Assets-69.15% Debt Debt-to-Equity Ratio6.65 Current Ratio2.38 Quick Ratio1.83 Sales & Book Value Annual Sales$107.67 million Price / Sales2.10 Cash FlowN/A Price / Cash FlowN/A Book Value$0.76 per share Price / Book2.51Miscellaneous Outstanding Shares118,890,000Free Float112,920,000Market Cap$226.49 million OptionableOptionable Beta0.86 Social Links Key ExecutivesBarry D. QuartChairman & Chief Executive OfficerJohn W. PoyhonenPresident & Chief Commercial OfficerDavid L. SzekeresChief Operating Officer & Executive Vice PresidentThomas B. OttoboniChief Scientific Officer & SVP-PharmaceuticalChris M. StorgardChief Medical OfficerKey CompetitorsRigel PharmaceuticalsNASDAQ:RIGLGeneration BioNASDAQ:GBIOAlpine Immune SciencesNASDAQ:ALPNPMV PharmaceuticalsNASDAQ:PMVPOmerosNASDAQ:OMERView All CompetitorsInsiders & InstitutionsPalisade Capital Management LPBought 397,263 shares on 3/24/2023Ownership: 3.184%Alliancebernstein L.P.Bought 16,100 shares on 2/16/2023Ownership: 0.149%Point72 Middle East FZEBought 14,878 shares on 2/16/2023Ownership: 0.013%Pier 88 Investment Partners LLCBought 32,300 shares on 2/15/2023Ownership: 0.050%Centiva Capital LPBought 16,888 shares on 2/15/2023Ownership: 0.026%View All Insider TransactionsView All Institutional Transactions HRTX Stock - Frequently Asked Questions Should I buy or sell Heron Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HRTX shares. View HRTX analyst ratings or view top-rated stocks. What is Heron Therapeutics' stock price forecast for 2023? 2 Wall Street research analysts have issued 12 month price targets for Heron Therapeutics' stock. Their HRTX share price forecasts range from $5.50 to $12.00. On average, they expect the company's stock price to reach $8.40 in the next year. This suggests a possible upside of 385.5% from the stock's current price. View analysts price targets for HRTX or view top-rated stocks among Wall Street analysts. How have HRTX shares performed in 2023? Heron Therapeutics' stock was trading at $2.50 at the beginning of 2023. Since then, HRTX stock has decreased by 30.8% and is now trading at $1.73. View the best growth stocks for 2023 here. When is Heron Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023. View our HRTX earnings forecast. How were Heron Therapeutics' earnings last quarter? Heron Therapeutics, Inc. (NASDAQ:HRTX) released its earnings results on Thursday, March, 23rd. The biotechnology company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.08. The biotechnology company earned $30 million during the quarter, compared to the consensus estimate of $27.24 million. Heron Therapeutics had a negative trailing twelve-month return on equity of 2,213.33% and a negative net margin of 169.05%. The firm's revenue was up 44.9% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.54) earnings per share. What ETFs hold Heron Therapeutics' stock? ETFs with the largest weight of Heron Therapeutics (NASDAQ:HRTX) stock in their portfolio include Jacob Forward ETF (JFWD) and Invesco Nasdaq Future Gen 200 ETF (QQQS).Global X Aging Population ETF (AGNG). What other stocks do shareholders of Heron Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Editas Medicine (EDIT), Immunomedics (IMMU), bluebird bio (BLUE), AT&T (T) and Amarin (AMRN). What is Heron Therapeutics' stock symbol? Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX." Who are Heron Therapeutics' major shareholders? Heron Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (9.98%), JPMorgan Chase & Co. (5.68%), Palisade Capital Management LLC NJ (3.18%), Palisade Capital Management LP (3.18%), Tang Capital Management LLC (3.16%) and ArrowMark Colorado Holdings LLC (3.00%). Insiders that own company stock include Craig A Johnson, David Leslie Szekeres, Kimberly Manhard and Waage Christian. View institutional ownership trends. How do I buy shares of Heron Therapeutics? Shares of HRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Heron Therapeutics' stock price today? One share of HRTX stock can currently be purchased for approximately $1.73. How much money does Heron Therapeutics make? Heron Therapeutics (NASDAQ:HRTX) has a market capitalization of $205.68 million and generates $107.67 million in revenue each year. The biotechnology company earns $-220,680,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis. How many employees does Heron Therapeutics have? The company employs 302 workers across the globe. Does Heron Therapeutics have any subsidiaries? The following companies are subsidiares of Heron Therapeutics: Heron Therapeutics B.V..Read More How can I contact Heron Therapeutics? Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.herontx.com. The biotechnology company can be reached via phone at (858) 251-4400, via email at ir@herontx.com, or via fax at 650-365-6490. This page (NASDAQ:HRTX) was last updated on 3/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.